Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy –

– Analysis of data from Phase 3 TRANSCEND trial show clinically meaningful changes in cardiometabolic parameters in patients with acquired hypothalamic obesity treated with setmelanotide for 52 weeks –

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Rhythm and its partners delivered four Rhythm data presentations at ObesityWeek® 2025, held last week in Atlanta, GA.

“Acquired hypothalamic obesity is a severe and complex disease that profoundly impacts the lives of patients and families, affecting not only body weight and hunger, but also causing severe implications for daily functioning,” said Christian Roth, M.D., Seattle Children’s Research Institute. “Multiple presentations at ObesityWeek showed that setmelanotide delivers robust reductions in BMI whereas previous studies testing anti-obesity medicines for the treatment of acquired hypothalamic obesity did not result in consistent sustained weight loss. Importantly, setmelanotide resulted in meaningful improvements in cardiometabolic health and patient-reported outcomes, highlighting its potential to transform the lives of patients living with acquired hypothalamic obesity.”

Dr. Roth delivered an oral presentation detailing previously disclosed results from a post-hoc analysis of Phase 3 TRANSCEND data of setmelanotide in patients with acquired hypothalamic obesity who received concomitant GLP-1 therapy during the trial. Highlights from the presentation include:

• -27.1% (p